Chantrix Is The Most Underrated Drug Today

I'm amazed at how little attention Chantrix is getting in the news today even though the success rate is through the roof. Pfizer expects sales to reach $500M by 2009. I think it'll be double that. More people are deciding to quit thanks to better education about the health risks of smoking (the leading preventable cause of death) not to mention the higher tobacco taxes in some states.

As reported in JAMA (Journal of the American Medical Association) Chantrix is twice as effective as Zyban. A study in 2006 included 1025 volunteer smokers who wanted to quit. The comparison was between Chantrix, Zyban and a placebo. After a year, the results were:

44% on Chantrix were not smoking at 12 weeks
29.5% on Zyban were not smoking at 12 weeks
18% on a placebo were not smoking at 12 weeks
22% on Chantrix did not smoke from week 9-52
16% on Zyban did not smoke from week 9-52
8.4% on a placebo did not smoke from week 9-52

This is a very significant success rate. Even more dramatic are the results among smokers who have smoked for more than two decades. A study will be published on this particular demographic soon. This is the real test of how effective a smoking cessation drug is. Based on personal experience and observation, I believe the results are going to astound everyone.

Chantrix is a miracle drug for my friends and family who otherwise would not have been able to quit. Interestingly, none of them would have heard about it unless I told them about it. With all the ads we see daily about erectile dysfunction, herpes suppression, and breast enhancement, you'd think a drug that is actually saving lives would get more attention.

Hopefully, Pfizer won't wait too long before spending as much on Chantrix advertising as they do on their other advertising.